vs
Adaptive Biotechnologies Corp（ADPT）とRepay Holdings Corp（RPAY）の財務データ比較。上の社名をクリックして会社を切り替えられます
Repay Holdings Corpの直近四半期売上が大きい（$78.6M vs $71.7M、Adaptive Biotechnologies Corpの約1.1倍）。Adaptive Biotechnologies Corpの純利益率が高く（-18.9% vs -178.3%、差は159.3%）。Adaptive Biotechnologies Corpの前年同期比売上増加率が高い（51.0% vs 0.4%）。Repay Holdings Corpの直近四半期フリーキャッシュフローが多い（$23.2M vs $1.4M）。過去8四半期でAdaptive Biotechnologies Corpの売上複合成長率が高い（30.8% vs -1.3%）
ExpreS2ionバイオテクノロジーズはデンマークのホルスホルムに本拠を置くバイオテクノロジー企業で、新規ワクチンと免疫療法製品の開発を専門としており、スウェーデンのナスダック・ファーストノース成長市場に上場しています。
Repay Holdings Corpは北米を主要市場とする決済テクノロジー企業で、小売、医療、自動車サービス、電子商取引などの業種の企業向けに、クレジット・デビットカード決済処理、ACH送金、POSシステム連携を含む統合決済ソリューションを提供し、顧客の業務効率化を支援しています。
ADPT vs RPAY — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $71.7M | $78.6M |
| 純利益 | $-13.6M | $-140.1M |
| 粗利率 | 74.6% | 74.2% |
| 営業利益率 | -17.8% | -182.2% |
| 純利益率 | -18.9% | -178.3% |
| 売上前年比 | 51.0% | 0.4% |
| 純利益前年比 | 59.7% | -3304.1% |
| EPS（希薄化後） | $-0.08 | $-1.68 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $71.7M | $78.6M | ||
| Q3 25 | $94.0M | $77.7M | ||
| Q2 25 | $58.9M | $75.6M | ||
| Q1 25 | $52.4M | $77.3M | ||
| Q4 24 | $47.5M | $78.3M | ||
| Q3 24 | $46.4M | $79.1M | ||
| Q2 24 | $43.2M | $74.9M | ||
| Q1 24 | $41.9M | $80.7M |
| Q4 25 | $-13.6M | $-140.1M | ||
| Q3 25 | $9.5M | $-6.4M | ||
| Q2 25 | $-25.6M | $-102.3M | ||
| Q1 25 | $-29.9M | $-7.9M | ||
| Q4 24 | $-33.7M | $-4.1M | ||
| Q3 24 | $-32.1M | $3.2M | ||
| Q2 24 | $-46.2M | $-4.1M | ||
| Q1 24 | $-47.5M | $-5.2M |
| Q4 25 | 74.6% | 74.2% | ||
| Q3 25 | 80.7% | 74.4% | ||
| Q2 25 | 69.4% | 75.7% | ||
| Q1 25 | 67.6% | 75.9% | ||
| Q4 24 | 62.0% | 76.3% | ||
| Q3 24 | 64.1% | 77.8% | ||
| Q2 24 | 55.3% | 78.2% | ||
| Q1 24 | 56.9% | 76.2% |
| Q4 25 | -17.8% | -182.2% | ||
| Q3 25 | 10.9% | -3.9% | ||
| Q2 25 | -42.5% | -138.7% | ||
| Q1 25 | -56.4% | -4.7% | ||
| Q4 24 | -71.3% | -1.5% | ||
| Q3 24 | -70.3% | -0.9% | ||
| Q2 24 | -109.6% | -4.6% | ||
| Q1 24 | -116.5% | -3.1% |
| Q4 25 | -18.9% | -178.3% | ||
| Q3 25 | 10.2% | -8.3% | ||
| Q2 25 | -43.5% | -135.2% | ||
| Q1 25 | -56.9% | -10.3% | ||
| Q4 24 | -71.0% | -5.3% | ||
| Q3 24 | -69.1% | 4.1% | ||
| Q2 24 | -107.0% | -5.4% | ||
| Q1 24 | -113.5% | -6.5% |
| Q4 25 | $-0.08 | $-1.68 | ||
| Q3 25 | $0.06 | $-0.08 | ||
| Q2 25 | $-0.17 | $-1.15 | ||
| Q1 25 | $-0.20 | $-0.09 | ||
| Q4 24 | $-0.22 | $-0.04 | ||
| Q3 24 | $-0.22 | $0.03 | ||
| Q2 24 | $-0.31 | $-0.04 | ||
| Q1 24 | $-0.33 | $-0.06 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $70.5M | $115.7M |
| 総負債低いほど良い | — | $280.1M |
| 株主資本純資産 | $218.8M | $484.4M |
| 総資産 | $512.7M | $1.2B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.58× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $70.5M | $115.7M | ||
| Q3 25 | $55.0M | $95.7M | ||
| Q2 25 | $43.2M | $162.6M | ||
| Q1 25 | $50.6M | $165.5M | ||
| Q4 24 | $47.9M | $189.5M | ||
| Q3 24 | $38.1M | $168.7M | ||
| Q2 24 | $59.8M | $147.1M | ||
| Q1 24 | $71.2M | $128.3M |
| Q4 25 | — | $280.1M | ||
| Q3 25 | — | $279.5M | ||
| Q2 25 | — | $279.0M | ||
| Q1 25 | — | $497.6M | ||
| Q4 24 | — | $496.8M | ||
| Q3 24 | — | $496.2M | ||
| Q2 24 | — | $435.6M | ||
| Q1 24 | — | $434.9M |
| Q4 25 | $218.8M | $484.4M | ||
| Q3 25 | $204.4M | $616.9M | ||
| Q2 25 | $179.7M | $633.7M | ||
| Q1 25 | $190.4M | $755.7M | ||
| Q4 24 | $202.7M | $761.3M | ||
| Q3 24 | $223.8M | $754.7M | ||
| Q2 24 | $241.6M | $815.4M | ||
| Q1 24 | $274.9M | $813.8M |
| Q4 25 | $512.7M | $1.2B | ||
| Q3 25 | $490.6M | $1.3B | ||
| Q2 25 | $496.6M | $1.4B | ||
| Q1 25 | $510.9M | $1.5B | ||
| Q4 24 | $539.4M | $1.6B | ||
| Q3 24 | $558.5M | $1.6B | ||
| Q2 24 | $584.9M | $1.5B | ||
| Q1 24 | $620.3M | $1.5B |
| Q4 25 | — | 0.58× | ||
| Q3 25 | — | 0.45× | ||
| Q2 25 | — | 0.44× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | — | 0.65× | ||
| Q3 24 | — | 0.66× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 0.53× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $2.1M | $23.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $1.4M | $23.2M |
| FCFマージンFCF / 売上 | 2.0% | 29.6% |
| 設備投資強度設備投資 / 売上 | 0.9% | 0.1% |
| キャッシュ転換率営業CF / 純利益 | — | — |
| 直近12ヶ月FCF直近4四半期 | $-48.9M | $90.7M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $2.1M | $23.3M | ||
| Q3 25 | $-7.1M | $32.2M | ||
| Q2 25 | $-12.4M | $33.1M | ||
| Q1 25 | $-28.5M | $2.5M | ||
| Q4 24 | $-12.5M | $34.3M | ||
| Q3 24 | $-27.1M | $60.1M | ||
| Q2 24 | $-17.3M | $31.0M | ||
| Q1 24 | $-38.4M | $24.8M |
| Q4 25 | $1.4M | $23.2M | ||
| Q3 25 | $-7.5M | $32.1M | ||
| Q2 25 | $-13.1M | $33.0M | ||
| Q1 25 | $-29.7M | $2.4M | ||
| Q4 24 | $-12.6M | $34.0M | ||
| Q3 24 | $-27.4M | $59.8M | ||
| Q2 24 | $-19.0M | $30.5M | ||
| Q1 24 | $-39.9M | $24.7M |
| Q4 25 | 2.0% | 29.6% | ||
| Q3 25 | -8.0% | 41.3% | ||
| Q2 25 | -22.2% | 43.6% | ||
| Q1 25 | -56.7% | 3.0% | ||
| Q4 24 | -26.5% | 43.5% | ||
| Q3 24 | -59.0% | 75.6% | ||
| Q2 24 | -44.1% | 40.7% | ||
| Q1 24 | -95.2% | 30.6% |
| Q4 25 | 0.9% | 0.1% | ||
| Q3 25 | 0.4% | 0.2% | ||
| Q2 25 | 1.1% | 0.1% | ||
| Q1 25 | 2.4% | 0.2% | ||
| Q4 24 | 0.2% | 0.3% | ||
| Q3 24 | 0.7% | 0.3% | ||
| Q2 24 | 4.0% | 0.6% | ||
| Q1 24 | 3.6% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 18.52× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
RPAY
| Sales Channel Directly To Consumer | $69.4M | 88% |
| Other | $6.8M | 9% |
| Sales Channel Through Intermediary | $2.3M | 3% |
